浙江丰立智能科技股份有限公司 2025 年半年度报告全文 证券代码：301368 证券简称：丰立智能 公告编号：2025-025 浙江丰立智能科技股份有限公司 Zhejiang FORE Intelligent Technology Co.,Ltd 2025 年半年度报告 2025 年 8 月 1 浙江丰立智能科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人王友利、主管会计工作负责人于玲娟及会计机构负责人(会计 主管人员)陈达声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及的未来的计划、业绩预测等方面的内容，均不构成本公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异，注意投资风险。 公司在本报告"第三节管理层讨论与分析"中"十、公司面临的风险和 应对措施"部分详细描述了公司经营中可能存 ...

Investment Rating - The report does not explicitly state an investment rating for the automotive industry or the embodied intelligence sector Core Insights - The embodied intelligence sector is entering a rapid implementation phase as of 2025, with multiple manufacturers planning mass production of robots across various applications [12][16][18] - The automotive industry is actively integrating embodied intelligence into its supply chain, leveraging existing technological advancements and manufacturing capabilities [34][37] - Government policies across various provinces are increasingly supportive of the embodied intelligence and robotics industries, aiming to foster innovation and market expansion [17][21][18] Summary by Sections 1. Rapid Development of Embodied Intelligence - The period from 2020 to 2025 marks a significant evolution in embodied intelligence, driven by advancements in AI and robotics, particularly following the release of OpenAI's ChatGPT3 [11] - Major manufacturers like Tesla and Xiaomi are entering the market, with Tesla predicting a production capacity of over 5,000 units by 2025 and 50,000 units by 2026 [13][16] - The demand for robots in various sectors is projected to grow significantly, with manufacturing being a primary area for automation due to its repetitive tasks [25][27] 2. Integration of Automotive and Embodied Intelligence - The automotive industry is leveraging its existing technological expertise in areas such as sensor fusion and control algorithms to facilitate the development of embodied intelligence [34][37] - Over ten automotive manufacturers are actively pursuing the embodied intelligence sector through self-development and strategic investments [36][37] - The shared supply chain for components like sensors and chips between automotive and robotics sectors is expected to reduce costs and enhance production efficiency [43][49] 3. Government Support and Policy Framework - Various provinces, including Shenzhen and Beijing, have introduced policies to support the development of embodied intelligence, focusing on technology breakthroughs and ecosystem building [17][21][18] - The policies aim to create a conducive environment for innovation, with specific targets for industry scale and technological advancements by 2027 [18][21] - The report highlights a collaborative approach among regions to drive the growth of the embodied intelligence sector, emphasizing the importance of technology and market integration [18][21]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Fengli Intelligent Technology Co., Ltd. as of July 30, 2025, indicating a decline in stock price and mixed financial results [1] - The company's stock closed at 62.38 yuan, down 1.76%, with a turnover rate of 5.83% and a trading volume of 37,400 lots, amounting to a transaction value of 234 million yuan [1] - There was a net outflow of main funds amounting to 24.63 million yuan, representing 10.52% of the transaction value, with significant outflows from large orders and super large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 117 million yuan, reflecting a year-on-year growth of 18.20%, while net profit attributable to shareholders decreased by 35.98% to 2.94 million yuan [1] - The company's liquidity ratios are as follows: current ratio at 1.222, quick ratio at 0.863, and a debt-to-asset ratio of 31.47% [1] - Fengli Intelligent has made investments in three companies, participated in 33 bidding projects, and holds 34 trademark registrations and 115 patents, along with 61 administrative licenses [2]

证券代码：301368 证券简称：丰立智能 公告编号：2025-022 浙江丰立智能科技股份有限公司 第三届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及子公司本次拟开展的外汇套期保值业务事项符合公司生产经营的实 际需要，公司针对外汇套期保值业务制定了切实可行的风险应对措施，不存在损 害上市公司及股东利益的情形。 具体内容详见同日披露在巨潮资讯网（www.cninfo.com.cn）上的《关于开展 外汇套期保值业务的公告》。 表决结果：9 票同意，0 票反对，0 票弃权。 三、备查文件 1、第三届董事会第七次会议决议； 特此公告。 一、董事会会议召开情况 浙江丰立智能科技股份有限公司（以下简称"公司"）第三届董事会第七次 会议于 2025 年 6 月 25 日以电话、电子邮件等方式通知全体董事，于 2025 年 6 月 30 日以现场结合通讯方式在公司会议室召开。本次会议由公司董事长王友利 先生召集和主持，应出席董事（含独立董事）9 人，实际出席董事 9 人，公司高 级管理人员列席了会议。本次会议的召开符合《公司法》和《公司章 ...

证券代码：301368 证券简称：丰立智能 公告编号：2025-021 浙江丰立智能科技股份有限公司 关于开展外汇套期保值业务的公告 一、外汇套期保值业务概述 （一）交易目的 公司及子公司在日常经营过程中涉及大量贸易项下外汇资金收付的外币业 务，为有效规避和防范外汇市场风险，防止汇率大幅波动对生产经营造成不利 影响，公司及子公司拟开展外汇套期保值业务，提高外汇资金使用效率，合理 降低财务费用。公司及子公司将以真实的业务为基础开展相关外汇套期保值业 务，不进行投机和套利交易。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 交易目的：浙江丰立智能科技股份有限公司（以下简称"公司"） 及子公司在日常经营过程中涉及大量贸易项下外汇资金收付的外币业务，为有 效规避和防范外汇市场风险，防止汇率大幅波动对生产经营造成不利影响，公 司及子公司拟开展外汇套期保值业务。 交易品种及工具：仅限于公司实际业务发生的结算币种，主要币种 有美元、欧元等。公司及子公司进行外汇套期保值业务包括但不限于远期业务 、掉期业务、互换业务、期权业务、期货业务及其他外汇衍生产品业务。 ...

国泰海通证券股份有限公司 公司及子公司在日常经营过程中涉及大量贸易项下外汇资金收付的外币业务，为有 效规避和防范外汇市场风险，防止汇率大幅波动对生产经营造成不利影响，公司及子公 司拟开展外汇套期保值业务，提高外汇资金使用效率，合理降低财务费用。公司及子公 司将以真实的业务为基础开展相关外汇套期保值业务，不进行投机和套利交易。 （二）交易金额 公司及子公司拟开展期限内任一交易日持有的最高合约价值不超过 5,000 万人民币 （或其他等值外币）的外汇套期保值业务，上述额度在有效期内可循环滚动使用，任一 时点的交易金额不超过授权的额度（含前述交易的收益进行再交易的相关金额）。 （三）交易方式 公司及子公司的外汇套期保值业务将在经国家外汇管理局和中国人民银行批准、具 有相应外汇套期保值业务经营资格的金融机构进行交易。外汇套期保值业务仅限于实际 业务发生的结算币种，主要币种有美元、欧元等。公司及子公司进行外汇套期保值业务 包括但不限于远期业务、掉期业务、互换业务、期权业务、期货业务及其他外汇衍生产 品业务。 关于浙江丰立智能科技股份有限公司 开展外汇套期保值业务的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通" ...

Core Viewpoint - The lithium iron phosphate (LFP) market is expected to maintain high growth in 2025, with significant production increases and market share dynamics among leading companies [2]. Group 1: Market Growth and Production - In the first half of 2025, LFP production reached 1.632 million tons, representing a year-on-year increase of 66.6% [3]. - The top company, Hunan Youneng, holds approximately 30% market share, significantly leading the first tier of companies [5]. - Hunan Youneng produced over 400,000 tons, far ahead of other top five companies, which produced between 100,000 to 150,000 tons each [7]. Group 2: Company Performance and Potential - Among the top 10 companies, Andar Technology and Dangsheng Technology exhibited the highest growth rates, both exceeding 200% [9]. - Other companies like Youshan Technology, Fulian Shenghua, and Guoxuan High-Tech also showed growth rates above 100% [9]. - Companies such as Wanhua Chemical, Dangsheng Technology, Xiexin Lithium Battery, Bangpu Recycling, and Ruixiang New Materials are emerging with strong financial capabilities and market ambitions, indicating potential for significant market presence in the future [9].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights that the turning point for research services has arrived, with a focus on companies such as Haoyuan Pharmaceutical, Bidai Pharmaceutical, and Baiaosaitu [1] - The A-share pharmaceutical index has seen a decline of 6.3% this week and an increase of 4.6% year-to-date, underperforming the CSI 300 by 3.9% and outperforming it by 2.3% respectively [4][9] - The report emphasizes the positive impact of recent policies accelerating the development of innovative drugs, which benefits upstream companies involved in research and production [4][18] Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 6.3% this week and increased by 4.6% year-to-date, while the H-share biotechnology index has dropped by 8.2% this week but increased by 48% year-to-date [4][9] - The report notes that the pharmaceutical sector has experienced significant declines, particularly in innovative drugs, with H-shares showing more pronounced drops due to previous high gains [4][9] Research and Development Progress - Recent policies have accelerated the approval processes for innovative drugs, with the FDA reducing NDA approval times from 10-12 months to 1-2 months, and China's CDE shortening IND review times from 60 days to 30 days [18][19] - The report indicates that the demand from the industrial sector is recovering, which will benefit early-stage research suppliers [20] Market Insights - The report suggests focusing on companies that are expected to benefit from the early-stage research demand, mergers and acquisitions, and the commercialization of innovative drugs [19] - Specific companies to watch include Haoyuan Pharmaceutical, Bidai Pharmaceutical, Baiaosaitu, and others in the life sciences service sector [4][19] Investment Strategy - The report recommends a ranking of sub-sectors for investment: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [11] - It highlights specific companies for investment based on growth potential, low valuations, and high dividend yields, particularly in the traditional Chinese medicine sector [11][13]

Group 1 - The core viewpoint of the article indicates that the company expects a significant increase in robot orders, projecting at least a 100% year-on-year growth in 2024, with even greater growth anticipated in the following year [1] - The company, Fengli Intelligent (301368), confirmed that the order quantity for its harmonic reducer products is sufficient to meet the expected demand [1]

证券代码：301368 证券简称：丰立智能 公告编号：2025-020 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江丰立智能科技股份有限公司（以下简称"公司")2024年度利润分配方案已获 2025年5月15日召开的2024年年度股东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过的利润分配情况 1、公司2024年年度股东大会审议通过的2024年度利润分配方案为：以截至2024年 12月31日公司总股本120,100,000股为基数，向全体股东按每10股派发现金股利0.67元 （含税），共分配现金股利8,046,700.00元（含税），本年度公司不送红股，不以资 本公积金转增股本。经上述分配后，剩余未分配利润全部结转以后年度。若在利润分 配预案公告日至实施利润分配方案的股权登记日期间，公司总股本发生变动的，公司 按照现金分红总额不变的原则对每股分红金额进行调整。 2、自分配方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与2024年年度股东大会审议通过的利润分配方案一致。 4、本次实施分配方案距离股东大会审议通过的时间未 ...